Every year, the Swedish Association of Urology organizes a national conference where about 1 000 participants from all over Sweden gather to share urological science and experience.
This year Cernelle hosted a Bronze sponsorship at the conference in Umeå, Sweden.
Associate Professors Ralph Peeker and Hans Hedelin attracted around 150 urologists and nurses to their seminar about Chronic Pelvic Pain Syndrome (CPPS);
“Chronic pelvic pain syndrome. What do we know and what do we think we know?”
Cernitol® Novum an OTC classified drug in Sweden was presented in the exhibition hall and created high interest from the delegates.
About AB Cernelle: Cernelle is a Swedish pharmaceutical company with research and development of medicine in urology; chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostate hyperplasia (BPH). Cernelle has developed herbal pharmaceuticals from pure pollen extract since 1953. With over 50 million daily doses per year, Cernilton®/Cernitol® is one of the world's most used medicine to treat benign prostate diseases.
The company is located outside Ängelholm in the Southern part of Sweden. To manage the ongoing expansion and growth, Cernelle expect to recruit 25-30 talented and skilled people within a three years period. Cernelle is owned by Backahill AB since 2005.